Better OS Derived From Matched Sibling Donor Vs Haploidentical Transplant in R/R ALL

Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.

Analysis of retrospective data revealed that matched sibling donor (MSD) transplants vs haploidentical stem cell transplant for patients with relapsed/refractory acute lymphoblastic leukemia (ALL) led to significantly higher overall survival (OS) at 2 years, according to a presentation at the 2022 Tandem Meeting.

Result showed that, at a median follow-up of 32 months, the 2-year OS rate was 38% in patients who underwent MSD transplant compared with 22% in those who had haploSCT (P = .001). Moreover, leukemia-free survival was 31% in the MSD-transplant arm vs 18% in the haploSCT group (P = .023), and graft-vs-host disease (GVHD)–free relapse-free survival rates were 19% vs 16%, respectively (P = .06).

“Two-year OS of relapsed/refractory patients with ALL undergoing MSD transplants is significantly better than in haploSCT with a higher [non-relapse mortality rate] with the latter,” lead study author Arnon Nagler, MD, MSc, president of the Hemato-Oncology Center, and director of Bone Marrow Transplantation and Cord Blood Bank, at Sheba Medical Center, and coinvestigators, wrote in a poster presentation. “The emerging humoral and cellular immunotherapies for ALL may enable reduction of the high posttransplantation relapse rates.”

Although previous data have demonstrated similar outcomes between MSD transplants and haploSCT for patients with ALL who are in remission, it is unclear if the same holds true for a relapsed/refractory population.

In the retrospective analysis, conducted by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, investigators evaluated 274 adult patients with relapsed/refractory ALL who underwent transplant, either through MSD or haploSCT, between 2012 and 2020. A multivariate analysis also adjusted for differences between groups through a Cox proportional hazards regression model.

Thirty-four percent (n = 94) of patients underwent haploSCT and 66% (n = 180) had MSD transplants. The median age was 33 years (range, 18-76) for those on the haploSCT group and 37 years (range, 18-76) on the MSD group. More patients in the MSD group were in primary refractory phrase (55.0%) than those in the haploSCT group (31.9%). However, more patients who underwent haploSCT were in their second relapse at 33% vs 11.1% who underwent MSD (P <.0001).

Moreover, 53.3% of patients had T-cell ALL, 25.5% had Philadelphia chromosome–negative disease, and 21.2% had Philadelphia chromosome–positive disease; these rates were similar between groups.

Additionally, the Karnofsky performance score was at least 90% in 59.8% and 64.7% of patients on the haploSCT and MSD-transplant arms, respectively (P <.43), and myeloablative conditioning regimens were given to 67% vs 84% of patients, respectively (P <.001). TBI was given to 32% vs 68% of patients, respectively (P <.0001). The use of bone marrow grafts was more common in those who underwent haploSCT (44%) compared with those who underwent MSD transplant (10%; P <.0001).

Engraftment rates were 87% in the haploSCT arm and 96% in the MSD-transplant arm (P = .005).

Further findings showed that acute GVHD that was stage II to IV did not significantly differ between the 2 arms, at 28% with haploSCT and 21% with MSD transplant, respectively (P = .25). Grade 3/4 GVHD occurred in 18% and 9% of patients, respectively (P = .042). Chronic GVHD rates were 17% and 33% in haploSCT and MSD-transplant arms, respectively (P = .012), and extensive cGVHD rates were 5% and 17%, respectively (P = .011).

The complete response (CR) rate was 64% in patients who underwent MSD transplant compared with 69% in those who had haploSCT. Relapse at 2 years occurred in 57% of those in the haploSCT group vs 52% in the MSD transplant group; non-relapse mortality (NRM) occurred in 25% vs 18% of patients, respectively.

When examined via multivariate analysis, NRM was higher with haploSCT than MSD transplant (HR, 2.03; 95% CI, 1.03-4.02; P = .042), which also was linked with worse OS with haploSCT (HR, 1.72; 95% CI, 1.15-2.58; P <.009).

Moreover, the multivariate analysis showed no difference between arms with regard to relapse (HR, 0.97; 95% CI, 0.62-1.52; P = .89), LFS (HR, 1.22; 95% CI, 0.84-1.78; P = .3), and GRFS (HR, 1.31; 95% CI, 0.88-1.94; P = .18). Non-significant differences in acute and chronic GVHD were observed between the 2 arms, as well.

Deaths in the haploSCT and MSD-transplant arms were caused by leukemia (64% vs 63%, respectively), infection (16% vs 18%), and GVHD (13% vs 11%).


Nagler A, Labopin M, Arat M, et al. Allogeneic stem cell transplantation from haploidentical versus matched sibling donors for adult patients with relapsed/refractory acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Presented at: 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; April 23-26, 2022; Salt Lake City, UT. Abstract 152.

Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content